alpha-aminopyridine has been researched along with Emesis in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Anthony, S; Bajaj, A; Bhundia, V; Branson, A; Brookes, C; Darlison, L; Dawson, AG; Fennell, DA; Gaba, A; Greystoke, A; Hutka, M; King, A; Mohammed, S; Morgan, B; Nusrat, N; Poile, C; Richards, C; Scotland, M; Thomas, A; Wells-Jordan, P | 1 |
| Chen, Z; Gao, Y; Guo, L; He, X; Huang, L; Huang, YY; Li, Z; Liang, J; Liang, SH; Luo, HB; Wu, D; Wu, R; Yu, S; Zhou, Q | 1 |
| Blokland, A; Heckman, PRA; Prickaerts, J; Sambeth, A; Uz, T; Van Duinen, MA | 1 |
| Horna, O; Toyas, C | 1 |
| Akkerman, S; Blokland, A; Creemers, P; De Vry, J; Prickaerts, J; Sambeth, A; Uz, T; van Duinen, M; Vanmierlo, T | 1 |
| Castellano, D; Chakravartty, A; Chi, KN; Csonka, D; de Bono, J; Dirix, L; Fizazi, K; Gravis, G; Machiels, JP; Maier, J; Massard, C; Mellado, B; Mita, A; Turri, S | 1 |
| Ball, D; Barnette, MS; Capper-Spudich, EA; Davis, TG; Ferrari, L; Knowles, RG; Kou, JP; Lucas, FS; Nials, AT; Peterson, JJ; Podolin, PL; Solanke, YE; Williamson, RA; Wiseman, J; Wren, P | 1 |
| Iwata, M; Kobayashi, M; Kubo, S; Ohtsu, Y; Shimizu, Y; Takahashi, K | 1 |
| Blouin, M; Brideau, C; Côté, B; Ducharme, Y; Frenette, R; Friesen, RW; Girard, Y; Laliberté, F; Masson, P; Prescott, S; Styhler, A | 1 |
| Boswell-Smith, V; Spina, D | 1 |
| Dunkman, WB; Franciosa, JA; Wilen, MM | 1 |
1 review(s) available for alpha-aminopyridine and Emesis
| Article | Year |
|---|---|
PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Diarrhea; Humans; Lung; Nausea; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory System Agents; Treatment Outcome; Vomiting | 2007 |
3 trial(s) available for alpha-aminopyridine and Emesis
| Article | Year |
|---|---|
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Topics: Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Diarrhea; Hemoptysis; Humans; Mesothelioma; Mesothelioma, Malignant; Pleural Neoplasms; Pulmonary Embolism; Respiratory Tract Infections; Sepsis; Thrombocytopenia; Vomiting | 2022 |
Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial.
Topics: Adolescent; Adult; Aminopyridines; Animals; Benzamides; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Male; Nausea; Phosphodiesterase 4 Inhibitors; Sensory Gating; Vomiting; Young Adult | 2018 |
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asthenia; Chills; Diarrhea; Fever; Humans; Hyperglycemia; Imidazoles; Kallikreins; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinolines; Stomatitis; Vomiting | 2017 |
7 other study(ies) available for alpha-aminopyridine and Emesis
| Article | Year |
|---|---|
Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dementia, Vascular; Dogs; Drug Design; Humans; Male; Mice, Inbred C57BL; Molecular Structure; Phosphodiesterase 4 Inhibitors; Protein Binding; Rolipram; Structure-Activity Relationship; Vomiting; Xanthones | 2020 |
[Intractable diarrhoea and severe weight loss by roflumilast].
Topics: Aged; Aminopyridines; Animals; Anorexia; Benzamides; Bronchitis; Comorbidity; Cyclopropanes; Diarrhea; Drug Evaluation, Preclinical; Female; Gastrointestinal Tract; Hallucinations; Hospitalization; Humans; Patient Readmission; Phosphodiesterase Inhibitors; Polypharmacy; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive; Sleep Apnea Syndromes; Vomiting; Weight Loss | 2013 |
The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
Topics: Aminopyridines; Animals; Benzamides; Cyclopropanes; Donepezil; Indans; Male; Memory; Mice; Mice, Inbred C57BL; Nootropic Agents; Phosphodiesterase 4 Inhibitors; Piperidines; Rats, Wistar; Recognition, Psychology; Rolipram; Scopolamine; Spatial Memory; Vomiting | 2016 |
The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in
Topics: Aminopyridines; Animals; Benzamides; Carboxylic Acids; Cyclohexanecarboxylic Acids; Cyclopropanes; Ferrets; Humans; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Neutrophils; Nitriles; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pica; Piperazines; Pyridines; Rats; Rats, Inbred Lew; Receptors, Adrenergic, alpha-2; Rolipram; Tumor Necrosis Factor-alpha; Vomiting | 2009 |
ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.
Topics: Adrenergic alpha-2 Receptor Antagonists; Aminopyridines; Animals; Benzamides; Blood Cells; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Enzyme Inhibitors; Ferrets; Interleukin-4; Lipopolysaccharides; Macrophages, Alveolar; Naphthyridines; Nitriles; Pneumonia; Rats; Tumor Necrosis Factor-alpha; Vomiting | 2011 |
Substituted aminopyridines as potent and selective phosphodiesterase-4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Bronchoconstriction; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Evaluation, Preclinical; Enzyme Inhibitors; Ferrets; Guinea Pigs; Half-Life; Humans; Inhibitory Concentration 50; Rats; Sheep; Structure-Activity Relationship; Therapeutic Equivalency; Tumor Necrosis Factor-alpha; Vomiting | 2003 |
Adverse effects of long-term amrinone administration in congestive heart failure.
Topics: Abdomen; Aged; Aminopyridines; Amrinone; Cough; Heart Failure; Humans; Liver Function Tests; Male; Middle Aged; Nausea; Pain; Time Factors; Vomiting | 1983 |